Abstract: Pharmaceutical compositions having as the active agent a compound of the formula ##STR1## useful for preventing allergic manifestations in sensitized mammals and novel compounds.
Abstract: A new method for synthesizing cholesta-5,7-diene-3.beta.,-25-diol and cholesta-5,7-diene-1.alpha.,3.beta.,25-triol has been discovered. ##STR1## wherein R is hydrogen or hydroxy. Various intermediates and reaction steps are claimed.
Abstract: Some new 4-amino-2-lower-alkyl-6-variable-pyridine-1-oxides are described. A new process is provided. The 6-variable is lower-alkyl, amino or substituted amino including saturated heterocyclic amino, e.g., pyrrolidinyl, piperidino, etc. The compounds are hypotensive agents and reduce blood pressure in animals.
Abstract: Novel compounds of the formula ##STR1## where R is hydrogen, a physiologically acceptable metal or amine cation, or alkyl of one to eight carbon atoms, inclusive, R.sub.1 is hydrogen, a physiologically acceptable metal or amine cation, or alkyl of one to eight carbon atoms, inclusive, are formulated into pharmaceutical compositions useful for preventing allergic manifestations in sensitized mammals.
Abstract: A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-.beta.-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene.
Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed which comprises administering to the mammal an effective amount of certain 1-pyridylalkyl-3-phenylthioureas. Disclosed also are novel substituted 1-pyridylalkyl-3-phenylthioureas and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.
Type:
Grant
Filed:
June 25, 1975
Date of Patent:
September 5, 1978
Assignee:
The Upjohn Company
Inventors:
William A. Callahan, Eldridge Myles Glenn, Douglas L. Rector
Abstract: Compounds represented below ##STR1## and pharmaceutical compositions thereof, the compositions including the non-substituted phenylene dioxamates are useful in the prophylactic treatment of sensitized mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.
Abstract: It has now been discovered that compounds of FIG. 1 ##STR1## are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation, or rectal means of administration. Certain compounds are novel.
Abstract: Compounds represented below ##STR1## and pharmaceutical compositions thereof, the compositions including the non-substituted phenylene dioxamates are useful in the prophylactic treatment of sensitized mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.
Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed, which comprises administering to the mammal an effective amount of certain 1-pyridylalkyl-3-phenylureas. Disclosed also are novel substituted 1-pyridylalkyl-3-phenylureas and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as, for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.
Type:
Grant
Filed:
December 2, 1976
Date of Patent:
May 9, 1978
Assignee:
The Upjohn Company
Inventors:
William A. Callahan, Eldridge M. Glenn, Douglas L. Rector
Abstract: A method of improving the endogenous production of prostaglandins by a mammal is disclosed, which comprises administering to the mammal an effective amount of an N-(pyridylalkyl)benzamides. Disclosed also are novel N-(pyridylalkyl)benzamides and therapeutic compositions thereof which are useful in carrying out the method of the invention.Disclosed also are methods of treating mammals for clinical conditions responsive to prostaglandins, such as for example, male infertility, epidermal injuries, atonic uterine bleeding, thromboembolic disease and like clinical conditions.
Type:
Grant
Filed:
June 25, 1975
Date of Patent:
January 17, 1978
Assignee:
The Upjohn Company
Inventors:
William A. Callahan, Eldridge Myles Glenn, Douglas L. Rector
Abstract: Compounds, compositions and methods of using the compounds of the formula as anti-allergics ##STR1## wherein X' is the same as X, X' is at the 3 or 4 position and is ##STR2##
Abstract: Some new 4-amino-2-lower-alkyl-6-variable-pyridine-1-oxides are described. A new process is provided. The 6-variable is lower-alkyl, amino or substituted amino including saturated heterocyclic amino, e.g., pyrrolidinyl, piperidino, etc. The compounds are hypotensive agents and reduce blood pressure in animals.
Abstract: It has now been discovered that novel compounds of FIG. 1 ##STR1## are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. Additionally, the compounds are intermediates to the diacid or di salts which have utility in the same area as the esters. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation, or rectal means of administration.
Abstract: Novel compounds of the formula ##STR1## wherein X is hydrogen, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro or bromo;R is hydrogen, alkyl of one to eight carbon atoms, inclusive, and a physiologically acceptable metal or amine cation and novel compositions wherein R is hydrogen or a physiologically acceptable metal or amine cation are used for prophylactically treating allergic disorders such as asthma.BRIEF SUMMARY OF THE INVENTIONIt has now been discovered that novel compounds of Formula I are useful in the prophylactic treatment of sensitized humans and animals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.
Abstract: A method of treating mammals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature which comprises administering prophylactically to said mammal an anti-allergy or anaphylactic reaction effective amount of a compound of the formula ##STR1## Novel compounds and compositions are also claimed.